バイオ医薬連携の失敗が新薬開発に与える影響を分析(When Promising Cures Collapse Before They Reach Patients)

ad

2026-04-24 ジョージア工科大学

ジョージア工科大学の研究は、有望とされた医療技術や治療法が臨床段階で失敗しても、その後患者に届く可能性がある過程を分析した。開発初期で有効性が期待された技術でも、試験結果や市場要因により一度は中断されることがあるが、改良や用途転換、他分野との統合を経て再び臨床応用に至るケースが確認された。研究はイノベーションの非線形性を示し、失敗とされる成果も知識蓄積や技術進化を通じて医療に貢献することを強調している。医療開発の評価や投資判断に新たな視点を提供する。

<関連情報>

Experiences, Experience Gaps, and the Moderating Role of Technology Co-Development in Biotech–Pharma Partnerships バイオテクノロジーと製薬のパートナーシップにおける経験、経験のギャップ、および技術共同開発の調整的役割

Stephan M Wagner, Manpreet S Hora, and Ivana Mateska
Production and Operations Management  Published:January 19, 2026
DOI:https://doi.org/10.1177/10591478261419268

Abstract

In the life sciences industry, pharmaceutical firms often collaborate with biotechnology firms to access technological expertise and R&D capabilities, enabling them to accelerate innovation and bring products to market more effectively. In this study, we examine the collaboration experiences of biotechnology startups and pharmaceutical firms in 287 biotech–pharma partnerships and analyze how firms’ experience impacts the likelihood of product commercialization. Experience is defined as the number of times each firm has participated in supply-based activities in biotech–pharma partnerships. We also conjecture that products developed through biotech–pharma partnerships are more likely to progress toward commercialization if both firms have similar levels of experience. However, when the partnering firms’ experience gap increases and they collaborate to develop the product jointly, we expect progress toward commercialization to become less likely. Our results show that both the biotechnology startup’s experience and the pharmaceutical firm’s experience increase the likelihood of progression toward commercialization. Our results also confirm that co-development moderates the relationship between experience gaps and the progression toward commercialization. Based on our findings, partnering experience and experience gaps are critical considerations as pharmaceutical firms engage in co-development projects with biotechnology startups. By focusing on partnering experience, our study contributes to the technology management literature and research on interfirm partnerships, specifically, in the biotechnology and pharmaceutical industries.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました